Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL-925 in Moderate to Severe Dry Eye Disease
NCT05745064Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2023
- Primary completion
- Jul 2023
- Countries
- 1
- Sponsor
- Telios Pharma
- Modality
- Small Molecules
- Drugs
- TL-925
- Conditions
- dry eye disease (DED)
01
Overview
Phase 2, randomised, double-blind trial in dry eye disease (DED) comparing TL-925 Arm with Placebo Arm (2 arms). Primary endpoint: Adverse events during screening & treatment period at 29 days. Started Feb 2023; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
TL-925 Arm
TL-925 ophthalmic emulsion 0.1% administered OU BID
Placebo Arm
Placebo (vehicle) administered OU BID
03
Who it enrols
Adults with moderate to severe dry eye disease diagnosed for at least 6 months, meeting specific criteria for Schirmer's test, TFBUT, and corneal/conjunctival staining.
04
Endpoints
Primary
Adverse events during screening & treatment period
Secondary
Change from baseline in corneal and conjunctival staining
Change from baseline in ocular discomfort
Change from baseline visual acuity
Beyond the preview
Go deeper on NCT05745064.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05745064.